Interval Debulking of Ovarian Cancer — An Interim Measure

Publisher Website
Google Scholar
Abstract
Ovarian cancer is the leading cause of death from gynecologic tumors and the fourth most frequent cause of death from cancer in women.1 At diagnosis, as many as 70 percent of women with the most common type of ovarian cancer, epithelial cancer, have advanced disease (stages III and IV).2 Fewer than 20 percent of patients with advanced cancer are alive five years after the diagnosis.3 Cytoreductive, or debulking, operations have become an established part of the treatment of advanced epithelial ovarian cancer.4,5 Although the operation has been used extensively, until now the survival benefit of debulking surgery itself has . . .